Matinas BioPharma Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Stockholders' Equity (Details Narrative)

Stockholders' Equity (Details Narrative) - USD ($)							1 Months Ended	12 Months Ended
Stockholders' Equity (Details Narrative) - USD ($)	Jun. 21, 2018	Jun. 21, 2018	Jun. 19, 2018	Sep. 12, 2016	Jul. 29, 2016	May 08, 2014	Aug. 31, 2013	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Aug. 16, 2016
Common stock par value								$ 0.0001	$ 0.0001
Net proceeds from exercise of warrants									$ 14,828,373
Common stock outstanding								113,287,670	93,371,129
Share-based payment award increase of shares offering date						January 1, 2015
Share-based payment award, percentage of outstanding stock maximum						4.00%
Stock Options [Member]
Option vested period								3 years
Number of option vested and exercisable								9,514,815
Option vested price per share								$ 1.17
Option intrinsic value								$ 500,000
Option intrinsic value price per share								$ 0.60
Unrecognized share-based compensation								$ 3,000,000
Share-based compensation weighted average period								2 years 2 months 12 days
Stock options expire term								10 years
Employee [Member]
Option vested period								4 years
Stock option shares vesting percentage								25.00%
2013 Equity Compensation Plan [Member]
Option granted description							Granted at prices not less than 100% of the fair value
Option vested period							3 years
Option term							The term of the options is no longer than ten years.
Number of common stock issued under plan								17,890,137
2017 Warrant Tender Offer [Member]
Number of warrant to purchase of common stock								30,966,350
Fair value of warrants								$ 15,500,000
Formation Warrants [Member]
Number of warrant to purchase of common stock								3,750,000
Merger Warrants [Member]
Number of warrant to purchase of common stock								754,000
2013 Investor Warrants
Number of warrant to purchase of common stock								7,243,750
Private Placement Warrants [Member]
Number of warrant to purchase of common stock								500,000
2015 Investor Warrants [Member]
Number of warrant to purchase of common stock								14,750,831
Placement Agent (PA) Warrants [Member]
Number of warrant to purchase of common stock								722,925
Class of warrant or right, exercise price of warrants or rights								$ 2.00
Warrant exercised on cashless basis								721,987
(PA) Warrants One [Member]
Number of warrant to purchase of common stock								1,426,687
Class of warrant or right, exercise price of warrants or rights								$ 1.00
Warrant exercised on cashless basis								1,424,812
(PA) Warrants Two [Member]
Number of warrant to purchase of common stock								1,818,157
Class of warrant or right, exercise price of warrants or rights								$ 0.75
Warrant exercised on cashless basis								1,774,017
Warrants [Member]
Number of warrant to purchase of common stock								5,799,429
Gross proceeds from exercise of warrants								$ 13,500,000
Net proceeds from exercise of warrants								$ 12,700,000
Common stock outstanding								58,159,495
Additional paid in capital inducement charges								$ 16,700,000
Issuance of warrants description								The Company may call the warrants, other than the Placement Agent Warrants, at any time the common stock trades above $ 3.00 (for 20 million warrants issued in 2015) for twenty (20) consecutive days
Warrants [Member] \| 2018 Placement Agent Warrants [Member]
Warrant term								5 years
Warrants [Member] \| Minimum [Member]
Class of warrant or right, exercise price of warrants or rights								$ 0.50
Warrants [Member] \| Maximum [Member]
Class of warrant or right, exercise price of warrants or rights								$ 0.75
Warrants [Member] \| Ageis Capital Corp [Member]
Warrant fee percentage								5.00%
Expenses and attorney fees								$ 35,000
Common Stock [Member]
Number share issued upon conversion									971,420
Number of warrant to purchase of common stock								40,255,234
Placement Agency Agreement [Member]
Gross proceeds of shares issued		$ 8,000,000
Net proceeds of shares issued		$ 7,100,000
Percentage of gross proceeds		7.00%
Percentage of non- accountable expenses		1.00%
Placement Agency Agreement [Member] \| 2018 Placement Agent Warrants [Member]
Number of warrant to purchase of common stock	240,000	240,000
Fair value of warrants	$ 89,000
Class of warrant or right, exercise price of warrants or rights	$ 0.75	$ 0.75
Warrant term	5 years	5 years
Series A Preferred Stock [Member]
Preferred stock shares authorized								10,000,000
Preferred stock par value								$ 0.001
Preferred stock shares designated								1,600,000
Preferred stock, shares outstanding								1,467,858
Preferred stock conversion basis								Series A Preferred Stock to be converted, multiplied by the stated value of $5.00 (the "Stated Value"), divided by the Conversion Price in effect at the time of the conversion (the initial conversion price is $0.50, subject to adjustment in the event of stock splits, stock dividends, and a "fundamental transaction").
Conversion price per share								$ 0.50
Number of preferred stock shares converted								14,678,580
Sale of stock price per share				$ 1.00	$ 0.67						$ 0.70
Intrinsic value								$ 4,400,000
Beneficial conversion feature amount										$ 4,400,000
Beneficial conversion feature percentage										100.00%
Dividend rate					8.00%			8.00%
Paid in kind dividend								$ 1,200,000
Dividends paid in shares of common stock								28,000
Dividend accumulated								$ 6,000
Royalty percentage				4.50%				7.50%
Series A Preferred Stock [Member] \| Sales Revenue, Net [Member]
Royalty percentage								4.50%
Series B Preferred Stock [Member]
Preferred stock shares designated			8,000
Preferred stock, shares outstanding								4,819
Conversion price per share								$ 0.50
Number of preferred stock shares converted								2,000
Dividend accumulated								$ 3,000
Stock conversion percentage								0.501
Beneficial ownership limitation description								The Beneficial Ownership Limitation, or such holder, together with such holder's affiliates, and any persons acting as a group together with such holder or affiliates, would beneficially own in excess of the Beneficial Ownership Limitation. The "Beneficial Ownership Limitation" is 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock issuable upon conversion of Series B Preferred Stock held by the applicable holder. A holder may, prior to issuance of the Series B Preferred Stock or, with 61 days prior notice to us, elect to increase or decrease the Beneficial Ownership Limitation; provided, however, that in no event may the Beneficial Ownership Limitation exceed 9.99%.
Liquidity value and dividends, description								(i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on the 12 month anniversary of the COD Effective Date, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on the 24-month anniversary of the COD Effective Date and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on the 36-month anniversary of the COD Effective Date. In the event a purchaser in this offering no longer holds Series B Preferred Stock as of the 12-month anniversary, the 24-month anniversary or the 36-month anniversary, such purchaser will not be entitled to receive any dividends on such anniversary date.
Liquidation value of preferred share value								$ 1,000
Series B Preferred Stock [Member] \| Holders [Member]
Conversion price per share								$ 0.50
Number of preferred stock shares converted								9,638,000
Series B Convertible Preferred Stock [Member]
Preferred stock shares authorized								8,000
Preferred stock par value								$ 1,000	$ 1,000
Preferred stock, shares outstanding								4,819
Series B Convertible Preferred Stock [Member] \| Placement Agency Agreement [Member]
Preferred stock par value			$ 0.0001
Number share issued upon conversion			8,000
Preferred stock stated value			$ 1,000
Common Stock [Member] \| Placement Agency Agreement [Member]
Conversion price per share			$ 0.50
Number share issued upon conversion			16,000,000
Common stock par value			$ 0.0001
Number of common shares issued			7,200,000